Structure-activity relationships in platelet activating factor. 9. From PAF-antagonism to PLA2 inhibition

Journal of Lipid Mediators and Cell Signalling

Volumn 15, Issue 2, 1997, Pages 125-144

  Binisti, Carine ^a   Touboul, Estera ^a   Mounier, Carine ^b   Heymans, Françoise ^a   Bon, Cassian ^b   Godfroid, Jean Jacques ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

inflammation; phospholipase A2 inhibitor; piperazine; structure activity relationship

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPID; PIPERAZINE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME RELEASE; INFLAMMATION; INFLAMMATORY DISEASE; MEDIATOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PANCREAS; PRIORITY JOURNAL; RABBIT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BLOOD PLATELETS; CATTLE; ENZYME INHIBITORS; MOLECULAR STRUCTURE; PANCREAS; PHOSPHOLIPASES A; PIPERAZINES; PLATELET ACTIVATING FACTOR; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031039754     PISSN: 09297855     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-7855(96)00453-1     Document Type: Article

References (44)

1. 2. J. Med. Chem. 37 (5), 557-560.
2. Behun, J.D. and Levine, R. (1961) The chemistry of pyrazine and its derivatives. IV. The alkylation and arylation of methylpyrazine. J. Am. Chem. Soc. 26, 3379-3382.
3. 2 and investigation by NMR and molecular modelling into the binding interactions in the enzyme-inhibitor complex. J. Med. Chem. 35, 2939-2951.
4. Binisti, C., Mounier, C., Touboul, E., Heymans, F., Bon, C. and Godfroid, J.J. (1996) Non substrate analogous inhibitors. 2. In vitro biochemical studies of PMS 832. J. Lipid Mediators Cell Signalling, submitted.
5. 2 and arthritis. Arthritis Rheum 36, 190-198.
6. 2 by the anti-inflammatory agent BMS-181162. J. Biol. Chem. 270 (1), 274-280.
7. 2+ dependent translocation domain with homology to PKC and GAP. Cell. 65, 1043-1051.
8. 2 from snake venom to human secreted forms. J. Mol. Evol. 31, 228-238.
9. 2 from human monocytic leukemic U937 cells. Calcium-dependent activation and membrane association. J. Biol. Chem. 265, 14654-14661.
10. 2 at 2.4 Å resolution. J. Mol. Biol. 124, 53-60.
11. Dive, G., Godfroid, J.J., Lamotte-Brasseur, J. et al. (1989) PAF-receptor. 1. Cache-oreilles effect of selected high potency platelet-activating factor (PAF) antagonists. J. Lipid Mediators 1, 201-215.
12. 2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br. J. Derm. 112, 135-147.
13. 2. FASEB 8, 916-924.
14. 2 based upon structural determinants. J. Biol. Chem. 252, 4913-4921.
15. 2 by the natural product, manoalide. Biochem. Pharmacol. 39, 1557-1564.
16. Jucker, E. and Rissi, E. (1962) Über C-substituierte piperazinderivate. Helv. Chim. Acta 45, 2383-2402.
17. Kornecki, E. and Ehrlich, Y. (1988) Neuroregulatory and neuropathological actions of the ether-phospholipid platelet-activating factor. Lipids. 26, 1243-1246.
18. Lamouri, A., Heymans, F., Tavet, F. et al. (1993) Design and modelling of new platelet-activating factor antagonists. 1. Synthesis and biological activities of 1,4-bis-(3′,4′,5′-trimethoxybenzoyl)-2-substituted carbonyl and carbamoyloxymethyl piperazines. J. Med. Chem. 36, 990-1000.
19. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35, 1593-1598.
20. 2. J. Pharm. Exp. Ther. 263, 1302-1307.
21. Moncada, S. and Higgs, E.A. (1988) Metabolism of arachidonic acid. Ann. New York Acad. Sci. 522, 454-463.
22. 2 is not required for arachidonic acid liberation during platelet activation. Eur. J. Biochem. 216, 169-175.
23. 2 activity by platelet-activating-factor antagonist Ro-19-3704 and evidence for a novel suppressive effect on platelet activation. J. Pharm. Exp. Ther. 264 (3), 1460-1467.
24. 2 in the human gastrointestinal tract. Lab. Invest. 72 (2), 201-208.
25. 2 inhibitors. J. Med. Chem. 34, 2260-2267.
26. 2 inhibitors. J. Med. Chem. 37, 337-341.
27. 2 using pyrene labeled phospholipid in the presence of serum albumin. Anal. Biochem. 117, 103-109.
28. 2 - kinetic characterization using the monomolecular film technique. Eur. J. Biochem. 204, 793-797.
29. Rekker, R.F. (1979) The hydrophobic fragmental constant; an extension to a 1000 data point set. Eur. J. Med. Chem. Chemother., 14 (6), 479-488.
30. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. and Serhan, C.N. (1987) Leukotriens and lipoxins: structure, biosynthesis and biological effects. Science 237, 1171-1176.
31. 2. Biochim. Biophys. Acta. 1044, 139-146.
32. 2 in a complex with a transition state analogue. Science 250, 1563-1566.
33. 2. Science 250, 1541-1546.
34. 2 from inflammatory exudate. Science 254, 1007-1010.
35. 2 is anti-hypotensive in a baboon E. coli-induced septic shock model. Prostaglandins Related Compounds, A151.
36. Stensland, B., Batt, J.P., Lamouri, A. and Godfroid, J.J. (1991) Platelet activating-factor antagonists. Structure of N,N′-bis(3,4,5-trimethoxybenzoyl)-2-piperazinylmethyl 2,2-dimethylpropanoate. Acta Crystallogr. C47, 1453-1457.
37. Tavet, F., Lamouri, A., Dive, G. et al. (1996) Design and modelling of new platelet activating-factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3′,4′,5′-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines. Relative importance of hydrophobicity and electronic distribution. J. Lipid Mediators Cell Signalling, in press.
38. A2 complexed with a substrate derived inhibitor. Nature 347, 689-691.
39. 2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediators 8, 1-30.
40. 2 expression and pathogenesis of the septis syndrome. Trends Shock Res. Circ. Shock. 39, 160.
41. 2 by acylamino phospholipid analogues. Biochim. Biophys. Acta 1124, 66-70.
42. 2 at 2.2 Å resolution. Nature 352, 79-82.
43. 2 in a complex with a transition state analogue. Science 250, 1560-1563.
44. 2 using amide substrate analogues. J. Am. Chem. Soc. 114 (23) 8757-8763.